COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Dupilumab Compassionate Use Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03020810
Expanded Access Status : Approved for marketing
First Posted : January 13, 2017
Last Update Posted : March 7, 2018
Information provided by (Responsible Party):
Sally E. Wenzel MD, University of Pittsburgh

Brief Summary:
This is a single patient expanded access, compassionate and non-emergency use study that provides patients with severe asthma, who do not qualify for ongoing clinical trials with dupilumab, access to this investigational treatment.

Condition or disease Intervention/treatment
Asthma Drug: Dupilumab

Detailed Description:

This study is being undertaken to determine whether dupilumab has efficacy in extremely severe asthma, and to allow a very severe asthma patient, who has been tried on nearly every immunosuppressive drug, early access to a potentially effective therapy.

The patient will continue in the study indefinitely. Safety will be evaluated and serious adverse events will be reported.

Layout table for study information
Study Type : Expanded Access
Official Title: Dupilumab Compassionate Use Study

Resource links provided by the National Library of Medicine

Drug Information available for: Dupilumab

Intervention Details:
  • Drug: Dupilumab
    The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Sever systemic corticosteroid dependent asthma for more than 5 years

Exclusion Criteria:

  • Disease other than asthma
  • Circulation eosinophils more than 1500/ul
  • Current smoker or more than 10 pack years

This is a single-patient study. The University of Pittsburgh site is not enrolling new patients.

No Contacts or Locations Provided
Layout table for additonal information
Responsible Party: Sally E. Wenzel MD, Professor of Medicine, University of Pittsburgh Identifier: NCT03020810    
Other Study ID Numbers: PRO16120334
First Posted: January 13, 2017    Key Record Dates
Last Update Posted: March 7, 2018
Last Verified: March 2018